Excision BioTherapeutics to Present at Upcoming Conferences
September 09, 2022 07:30 ET
|
Excision BioTherapeutics
SAN FRANCISCO, Sept. 09, 2022 (GLOBE NEWSWIRE) -- Excision BioTherapeutics Inc., a clinical-stage biotechnology company developing CRISPR-based therapies intended to cure viral infectious diseases,...
Excision BioTherapeutics to Participate in the Jefferies Healthcare Conference on Thursday, June 9, 2022 at 2:00 p.m. ET
June 07, 2022 16:05 ET
|
Excision BioTherapeutics
SAN FRANCISCO, June 07, 2022 (GLOBE NEWSWIRE) -- Excision BioTherapeutics Inc., a biotechnology company developing CRISPR-based therapies intended to cure viral infectious diseases, today announced...
Excision BioTherapeutics to Present Preclinical and Bioinformatic Data Showing Robust and Specific Editing of HIV Proviral DNA with EBT-101 at the ASGCT 25th Annual Meeting
May 17, 2022 08:00 ET
|
Excision BioTherapeutics
EBT-101 achieves HIV excision without detectable off-target effectsPoster presentation to take place today from 5:30 – 6:30 PM ET SAN FRANCISCO, May 17, 2022 (GLOBE NEWSWIRE) -- Excision...
Excision BioTherapeutics Initiates Phase 1/2 Trial Evaluating EBT-101 as a Potential Cure for HIV
January 27, 2022 07:30 ET
|
Excision BioTherapeutics
EBT-101 is a CRISPR-based therapeutic being developed as a potential functional cure for people living with HIVFirst-in-human trial is now open for enrollment SAN FRANCISCO, Jan. 27, 2022 (GLOBE...
Excision BioTherapeutics Expands Management Team with Three Key Appointments
October 12, 2021 08:00 ET
|
Excision BioTherapeutics
Sara Turken, J.D., as General CounselManish Anand, M.Sc., as Senior Vice President, Regulatory AffairsRobert Gunning, CPA, CGMA, as VP, Controller SAN FRANCISCO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- ...
Excision Receives FDA Clearance of IND for Phase 1/2 Trial of EBT-101 CRISPR-Based Therapeutic for Treatment of HIV
September 15, 2021 08:00 ET
|
Excision BioTherapeutics
EBT-101, first-in-human CRISPR-based one-time gene therapy to be evaluated in individuals with HIVInitiation of EBT-101 Phase 1/2 clinical trial expected later this year SAN FRANCISCO, Sept. 15,...
Excision Announces NIH Martin Delaney Grant Awarded to Temple University to Support “CRISPR for Cure” for HIV
August 26, 2021 08:00 ET
|
Excision BioTherapeutics
CRISPR-based therapies as a curative approach to HIV infection included in the program for first time.Collaboration with Temple University includes research on EBT-101, a CRISPR-based therapeutic...
Excision BioTherapeutics Appoints Industry Veteran Lisa Danzig, M.D., as Chief Medical Officer
July 29, 2021 08:00 ET
|
Excision BioTherapeutics
SAN FRANCISCO, July 29, 2021 (GLOBE NEWSWIRE) -- Excision BioTherapeutics Inc, the developer of CRISPR-based therapies intended to cure viral infectious diseases, today announced the appointment of...
Excision BioTherapeutics Appoints Infectious Disease Expert Sumathi Sivapalasingam, M.D, as Head of Translational Medicine
May 27, 2021 08:00 ET
|
Excision BioTherapeutics
SAN FRANCISCO, May 27, 2021 (GLOBE NEWSWIRE) -- Excision BioTherapeutics (“Excision”), a leading developer of potentially curative CRISPR anti-viral therapies to improve patient lives, today...
Excision BioTherapeutics Appoints Biotechnology Development and Manufacturing Veteran, Franz Gerner, Ph.D., as Chief Technology Officer & Head of Manufacturing
May 24, 2021 08:00 ET
|
Excision BioTherapeutics
SAN FRANCISCO, May 24, 2021 (GLOBE NEWSWIRE) -- Excision BioTherapeutics (“Excision”), a leading developer of potentially curative CRISPR anti-viral therapies to improve patient lives, today...